There is potential impact on the heart, coronary arteries, and heart function following radiation to the left side of the body, explained Amresh Raina, MD, director of the Advanced Heart Failure and Pulmonary Hypertension Program at Allegheny General Hospital and the Allegheny Health Network in Pittsburgh, Pennsylvania.
There is potential impact on the heart, coronary arteries, and heart function following radiation to the left side of the body; however, radiation has evolved such that you can target it to avoid the heart and chest, explained Amresh Raina, MD, director of the Advanced Heart Failure and Pulmonary Hypertension Program at Allegheny General Hospital and the Allegheny Health Network in Pittsburgh, Pennsylvania, is a board-certified advanced heart failure cardiologist, who is also certified in echocardiography and general cardiology.
Transcript
Does left-side radiation have a higher association with cardiac issues?
That’s a good question. Radiation has evolved in the last 50 years. When radiation therapy was first developed, it was largely whole-body radiation, so you'd get sort of a nonspecific and nontargeted area of radiation. Obviously, if you're doing radiation to the left side of the body, left side of the chest specifically, there's a higher incidence of it having some impact upon the heart and the coronary arteries and the heart function. If you're getting a radiation to the brain, for example, you're less likely to have a significant exposure in the chest, or if you're getting radiation to the pelvis, similarly, you can usually target it to avoid the chest and the heart as much as possible. So, there is more targeted radiation now than there was many years ago, but obviously the risk is higher when it's on the left side of the chest vs some other portion of the body.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More